Immunoadjuvant Chemotherapy of Visceral Leishmaniasis in Hamsters Using Amphotericin B-Encapsulated Nanoemulsion Template-Based Chitosan Nanocapsules
- 1 April 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (4) , 1714-1722
Abstract
The accessible treatment options for life-threatening neglected visceral leishmaniasis (VL) disease have problems with efficacy, stability, adverse effects, and cost, making treatment a complex issue. Here we formulated nanometric amphotericin B (AmB)-encapsulated chitosan nanocapsules (CNC-AmB) using a polymer deposition technique mediated by nanoemulsion template fabrication. CNC-AmB exhibited good steric stabilityin vitro, where the chitosan content was found to be efficient at preventing destabilization in the presence of protein and Ca2+. A toxicity study on the model cell line J774A and erythrocytes revealed that CNC-AmB was less toxic than commercialized AmB formulations such as Fungizone and AmBisome. The results ofin vitro(macrophage-amastigote system; 50% inhibitory concentration [IC50], 0.19 ± 0.04 μg AmB/ml) andin vivo(Leishmania donovani-infected hamsters; 86.1% ± 2.08% parasite inhibition) experiments in conjunction with effective internalization by macrophages illustrated the efficacy of CNC-AmB at augmenting antileishmanial properties. Quantitative mRNA analysis by real-time PCR (RT-PCR) showed that the improved effect was synergized with the upregulation of tumor necrosis factor alpha (TNF-α), interleukin-12 (IL-12), and inducible nitric oxide synthase and with the downregulation of transforming growth factor β (TGF-β), IL-10, and IL-4. These research findings suggest that a cost-effective CNC-AmB immunoadjuvant chemotherapeutic delivery system could be a viable alternative to the current high-cost commercial lipid-based formulations.Keywords
This publication has 52 references indexed in Scilit:
- Elongation Factor-2, a Th1 Stimulatory Protein of Leishmania donovani, Generates Strong IFN-γ and IL-12 Response in Cured Leishmania-Infected Patients/Hamsters and Protects Hamsters against Leishmania ChallengeThe Journal of Immunology, 2011
- Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasisJournal of Microencapsulation, 2011
- Molecular docking, structure–activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovaniJournal of Antimicrobial Chemotherapy, 2010
- Inhibition of ABC Transporters Abolishes Antimony Resistance inLeishmaniaInfectionAntimicrobial Agents and Chemotherapy, 2008
- Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasisJournal of Drug Targeting, 2007
- Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental modelsParasitology Research, 2005
- Cloning of S -Adenosyl- l -Methionine:C-24-Δ-Sterol-Methyltransferase (ERG6) from Leishmania donovani and Characterization of mRNAs in Wild-Type and Amphotericin B-Resistant PromastigotesAntimicrobial Agents and Chemotherapy, 2004
- Receptor-mediated stimulatory effect of oligochitosan in macrophagesBiochemical and Biophysical Research Communications, 2004
- Toxicity of amphotericin B emulsion formulationsJournal of Antimicrobial Chemotherapy, 1993
- Chitosan-as a BiomaterialBiomaterials, Artificial Cells and Artificial Organs, 1990